Author

K. Guilfoyle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

G. van Amerongen· 2 shared A. D. Osterhaus· 1 shared A. Huckriede· 1 shared A. Lafferty· 1 shared A. Z. Mykytyn· 1 shared B. J. Bosch· 1 shared B. L. Haagmans· 1 shared C. A.M. de Haan· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

G. van Amerongen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

W. Du, D. L. Hurdiss, D. Drabek, A. Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M. M. Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, , B. J. Bosch

bioRxiv · Feb 17, 2022 · PreprintMicrobiology

Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster model

J. Climax, M. Hamza, A. Lafferty, K. Guilfoyle, G. van Amerongen, K. Stadler, P. Wohlsein, W. Baumgärtner, M. Weissbach, D. Coughlan

This study shows that epeleuton reduces SARS-CoV-2 viral load, replication, and lung pathology in Syrian hamsters when administered orally.

bioRxiv · Dec 7, 2021 · PreprintMicrobiology

Cross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccines

W. Dong, Y. Bhide, F. Sicca, T. Meijerhof, K. Guilfoyle, O. G. Engelhardt, L. Boon, C. A.M. de Haan, G. Carnell, N. Temperton, J. de Vries-Idema, D. J. Kelvin, A. Huckriede

This study shows that sequential vaccination with inactivated influenza vaccines can reduce pandemic virus infection severity, while subunit vaccines cannot, through cross-reactive antibodies and CD8+ T cells.

bioRxiv · May 31, 2018Microbiology